Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Summary

To evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.

Timeline

Start

2023-06-13

Primary completion

2024-10-13

Completion

2024-10-13

Drugs

Indications